What is Zacks Research’s Estimate for Integer Q1 Earnings?

Integer Holdings Corporation (NYSE:ITGR) – Investment analysts at Zacks Research lowered their Q1 2026 earnings per share estimates for shares of Integer in a research report issued to clients and investors on Thursday, November 13th. Zacks Research analyst Team now forecasts that the medical equipment provider will post earnings per share of $1.39 for the quarter, down from their prior forecast of $1.58. The consensus estimate for Integer’s current full-year earnings is $6.01 per share.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Integer in a research report on Friday, October 31st. Truist Financial decreased their target price on shares of Integer from $121.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, October 24th. Piper Sandler lowered their price target on shares of Integer from $155.00 to $82.00 and set an “overweight” rating for the company in a report on Friday, October 24th. Argus lowered shares of Integer from a “buy” rating to a “hold” rating in a report on Friday, October 24th. Finally, Wells Fargo & Company restated an “equal weight” rating and set a $80.00 target price (down from $132.00) on shares of Integer in a research note on Friday, October 24th. Four investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $96.75.

Integer Price Performance

Integer stock opened at $69.45 on Friday. Integer has a 1 year low of $62.00 and a 1 year high of $146.36. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.45 and a current ratio of 3.71. The firm has a 50 day moving average price of $91.70 and a 200 day moving average price of $107.10. The company has a market cap of $2.43 billion, a price-to-earnings ratio of 29.06, a PEG ratio of 0.60 and a beta of 0.95.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, October 23rd. The medical equipment provider reported $1.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.11. Integer had a return on equity of 12.84% and a net margin of 4.75%.During the same quarter in the previous year, the firm earned $1.43 earnings per share. The business’s revenue was up 8.4% on a year-over-year basis. Integer has set its FY 2025 guidance at 6.290-6.430 EPS.

Hedge Funds Weigh In On Integer

Hedge funds have recently made changes to their positions in the business. Schonfeld Strategic Advisors LLC boosted its stake in shares of Integer by 109.9% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 12,445 shares of the medical equipment provider’s stock worth $1,286,000 after acquiring an additional 6,517 shares during the period. Creative Planning increased its holdings in shares of Integer by 8.1% in the third quarter. Creative Planning now owns 9,689 shares of the medical equipment provider’s stock valued at $1,001,000 after purchasing an additional 723 shares during the last quarter. Raymond James Financial Inc. raised its position in shares of Integer by 14.3% in the third quarter. Raymond James Financial Inc. now owns 330,317 shares of the medical equipment provider’s stock valued at $34,132,000 after purchasing an additional 41,209 shares during the period. Amundi raised its holdings in Integer by 5.3% in the 3rd quarter. Amundi now owns 6,180 shares of the medical equipment provider’s stock valued at $651,000 after acquiring an additional 310 shares during the period. Finally, Freestone Grove Partners LP lifted its position in Integer by 17.9% during the third quarter. Freestone Grove Partners LP now owns 3,658 shares of the medical equipment provider’s stock worth $378,000 after acquiring an additional 555 shares during the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

Insider Transactions at Integer

In related news, VP Tommy P. Thomas sold 884 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $70.15, for a total value of $62,012.60. Following the sale, the vice president directly owned 3,596 shares in the company, valued at $252,259.40. The trade was a 19.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Payman Khales purchased 3,127 shares of the company’s stock in a transaction that occurred on Thursday, October 30th. The stock was bought at an average cost of $64.94 per share, for a total transaction of $203,067.38. Following the purchase, the chief executive officer directly owned 22,865 shares in the company, valued at $1,484,853.10. This represents a 15.84% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 5,843 shares of company stock valued at $384,771 in the last quarter. Company insiders own 2.16% of the company’s stock.

Integer declared that its Board of Directors has authorized a share buyback program on Tuesday, November 4th that permits the company to buyback $200.00 million in outstanding shares. This buyback authorization permits the medical equipment provider to buy up to 8.3% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.